<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03260153</url>
  </required_header>
  <id_info>
    <org_study_id>CBS-ICH</org_study_id>
    <nct_id>NCT03260153</nct_id>
  </id_info>
  <brief_title>Deproteinised Calf Blood Serum Injection for the Treatment of Acute Intracerebral Hemorrhage</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Stroke Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Tiantan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy and safety of Deproteinised Calf
      Blood Serum Injection in alleviating perihematomal edema (PHE) and secondary brain injury, as
      well as neurologic deficits in patients with acute intracerebral hemorrhage (ICH).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study hypothesized that administration of Deproteinised Calf Blood Serum Injection would
      alleviate PHE and secondary brain injury, thus improving clinical outcomes in patients with
      ICH. The investigators will enroll 60 acute supratentorial ICH patients. Patients will be
      assigned randomly to receive either Deproteinised Calf Blood Serum Injection or placebo
      treatment, which is blinded to evaluator and patients. All patients in the study will receive
      standard care treatment and clinical, diagnostic, laboratory, safety, and follow-up
      evaluations. Blood will be drawn and brain MRI will be done in different time course.
      Follow-up evaluations, including National Institute of Health stroke scale(NIHSS), Stroke
      impact scale , Glasgow Coma Scale ,Barthel index score and modified Rankin scale assessments,
      will be done periodically until 90 days after onset.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2017</start_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of cytotoxic and vasogenic edema on day 3 and day 7-10 (MRI evaluation)</measure>
    <time_frame>day 3, day 7-10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of vasogenic edema on day 14 (CT evaluation)</measure>
    <time_frame>day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of the biomarkers（MMP3、MMP9、TNF-α、IL-6、CRP） in the peripheral blood on different time course.</measure>
    <time_frame>at admission, day 3，day 3-7，day 14，day 30, day 90</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome evaluated by Glasgow Coma Scale(GCS)scores.</measure>
    <time_frame>at admission, day 14， day 30， day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome evaluated by NIH Stroke Scale(NIHSS)scores.</measure>
    <time_frame>at admission, day 14， day 30， day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome evaluated by Barthel Index(BI) scores.</measure>
    <time_frame>day 14， day 30， day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome evaluated by Modified Rankin Scale(mRS)scores.</measure>
    <time_frame>at admission, day 14， day 30， day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcome evaluated by Stroke Impact Scale (SIS) scores.</measure>
    <time_frame>day 90</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Intracerebral Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Deproteinised Calf Blood Serum Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomly assigned to receive Deproteinised Calf Blood Serum Injection or placebo within 1 hour after randomization, once a day for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium Chloride Physiological Solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be randomly assigned to receive Deproteinised Calf Blood Serum Injection or placebo within 1 hour after randomization, once a day for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deproteinised Calf Blood Serum Injection</intervention_name>
    <arm_group_label>Deproteinised Calf Blood Serum Injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Sodium Chloride)</intervention_name>
    <arm_group_label>Sodium Chloride Physiological Solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of spontaneous intracerebral hemorrhage(sICH)

          2. Bleeding into deep gray matter (basal ganglionic and thalamus), and the amount of
             bleeding between 5 and 30 ml;

          3. Age between 18 and 80 years;

          4. Presentation within 48 hours of symptom onset, and NCCT at 24 hours need to be done in
             patients presenting within 24 hours of symptom onset in order to exclude hematoma
             expansion.

          5. Informed consent by patients or relatives.

        Exclusion Criteria:

          1. Â secondary ICH (secondary to trauma, tumor, vascular malformations, ischemic stroke
             hemorrhagic transformation, etc.);

          2. Glasgow Coma Score of 3-8 at admission;

          3. Parenchymal hemorrhage with ventricle involved;

          4. Patients with hematoma expansion; .

          5. Planned surgery within 3 days of symptom onset;

          6. Incompletely absorbed brain hematoma previously;

          7. Prestroke modified Rankin score(mRS)&gt;1;

          8. Patients with hemorrhagic disease or coagulation disorders;

          9. Patients with severe liver and renal insufficiency;.

         10. Patients with severe heart failure or other serious systemic diseases;

         11. Patients with malignant tumors or ongoing anti-tumor therapy;

         12. Patients with a history of dementia or mental disorders;

         13. Pregnant or lactating women or those who has a recent fertility plan;

         14. Any contraindications to MRI(such as cardiac pacemakers and other metal implants,
             claustrophobia);

         15. Any other neuroprotective has been applied before randomization;

         16. Terminal patients whose life expectancy &lt;90 days;

         17. Patients participating in other clinical trials 30 days prior to randomization.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xingquan Zhao, MD</last_name>
    <phone>8610-67098891</phone>
    <email>zxq@vip.163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Tian Tan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xingquan Zhao, MD</last_name>
      <phone>8610-67098891</phone>
      <email>zxq@vip.163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2017</study_first_submitted>
  <study_first_submitted_qc>August 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2017</study_first_posted>
  <last_update_submitted>August 28, 2017</last_update_submitted>
  <last_update_submitted_qc>August 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Tiantan Hospital</investigator_affiliation>
    <investigator_full_name>Xingquan Zhao</investigator_full_name>
    <investigator_title>Professor of Neurology and Stroke Center</investigator_title>
  </responsible_party>
  <keyword>Intracerebral Hemorrhage</keyword>
  <keyword>Perihematomal edema</keyword>
  <keyword>Deproteinised Calf Blood Serum Injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Cerebral Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

